Anti-CD38 Single-Domain Antibodies Prevent Surface Downregulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current theranostic agents for neoplastic diseases, such as those targeting CD38, often induce internalization of the CD38 antigen-antibody complex, leading to downregulation of CD38 expression on cell surfaces, which hampers effective imaging and therapeutic targeting.
Innovation Solution
Development of anti-CD38 single-domain antibodies (sdAbs) that minimize internalization of the CD38 antigen-antibody complex, allowing preserved surface expression and enabling combination therapies or imaging/diagnostic applications without competition with existing antibodies like daratumumab.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-CD38 antibodies (e.g., daratumumab) are used for therapeutic targeting, then therapeutic effect is achieved through CD38 antigen-antibody complex formation, but CD38 expression on cell surface is downregulated due to internalization
Solution Approach 1:
The patent uses single-domain antibodies (sdAbs) as segmented, minimalistic antibody units that bind to CD38 without triggering full internalization pathways. These sdAbs are derived from camelid heavy-chain antibodies and represent a segmented approach to antibody therapy, using only the essential antigen-binding domain rather than full-length antibodies, thereby achieving therapeutic effect while preserving surface expression.
Solution Approach 2:
The invention changes the molecular parameters of the antibody by using single-domain antibodies with different structural and functional properties compared to conventional full-length antibodies. This parameter change in antibody structure (from full-length to single-domain) fundamentally alters the interaction dynamics with CD38, preventing internalization while maintaining binding affinity and therapeutic effect.
2Reliability
If anti-CD38 antibodies induce internalization of the antigen-antibody complex, then therapeutic killing effect is enhanced, but imaging and diagnostic capabilities are compromised due to loss of surface antigen
Solution Approach 1:
The patent segments the therapeutic and diagnostic functions by using different antibody modalities: single-domain antibodies for therapy that preserve surface expression, and separate imaging agents for diagnostics. This segmentation allows each function to be optimized independently without the trade-off present in conventional approaches.
Solution Approach 2:
The invention introduces an intermediary approach where single-domain antibodies serve as a mediator that binds CD38 with high affinity for therapeutic effect while their unique structural properties prevent internalization, thereby maintaining the antigen available for subsequent imaging and diagnostic procedures.
3Reliability
If existing anti-CD38 antibodies are used for imaging and therapy, then targeting capability is achieved, but combination therapies are limited due to epitope competition
Solution Approach 1:
The patent applies local quality by targeting different epitopes on the CD38 molecule. The single-domain antibodies recognize specific local regions (epitopes) on CD38 that are distinct from those recognized by daratumumab and other conventional antibodies. This epitope-specific binding allows multiple antibodies to bind simultaneously without competition, enabling combination therapies with enhanced versatility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-CD38 sdAbs maintain CD38 expression on cell surfaces, facilitating enhanced imaging and therapeutic targeting by preventing downregulation, and allow for concurrent use with daratumumab in combination therapies.
Implementation Method 1
the present anti-CD38 sdAbs bind to CD38 epitopes other than the epitope recognised by daratumumab
Data Source
AI summary
The present invention relates to medical imaging, disease monitoring and theranostic approaches in neoplastic diseases of certain anti-CD38 single-domain antibodies (sdAb).